Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Muscle-Guided rehab shows promise for stroke recovery

NCT ID NCT07531264

Symptom relief Sponsor: University of Houston Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of physical therapy called NICE rehabilitation for people who have had a stroke and have weakness on one side. The therapy uses a computer to show patients how to activate specific muscles, helping them regain arm movement. Researchers will measure changes in motor function and muscle coordination in 48 adults aged 21 to 80.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2027

An estimate. Start dates often move.

Expected to finish

Aug 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for individuals after stroke are: * Hemiparetic chronic stroke survivors more than 6 months after stroke onset * Adults aged 21-80 years, including both female and male participants * Individuals with a single unilateral ischemic or hemorrhagic stroke * Individuals with Upper Extremity Fugl-Meyer Assessment score between 10 and 59 out of 66 * Individuals who have not received botulinum toxin injections in the upper extremity within the past 3 months * Individuals without severe spasticity, defined as Modified Ashworth Scale score ≤3 at the elbow and shoulder Exclusion criteria for individuals after stroke are: * Individuals younger than 21 years of age or older than 80 years of age * Individuals with an orthopedic disorder involving the upper limbs * Individuals unable to produce voluntary upper-extremity muscle EMG activity; * Individuals with cognitive impairment sufficient to interfere with informed consent or successful completion of the protocol, assessed using the Montreal Cognitive Assessment or other IRB-approved screening procedures. * Individuals whose stroke-affected arm has an intermuscular coordination pattern similarity score \>0.80 relative to the non-affected arm Inclusion criteria for healthy individuals are: * Healthy adults aged 21-80 years, including both female and male participants * Individuals with no known neurological or orthopedic injuries Exclusion criteria for healthy individuals are: * Individuals younger than 21 years of age or older than 80 years of age * Individuals with known neurological disorders * Individuals with orthopedic injuries or conditions affecting upper-extremity movement * Individuals unable to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic stroke Chronic stroke-related upper-extremity motor impairment Hemiparetic stroke Motor module-guided rehabilitation targeting impaired intermuscular coordination and motor recovery Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Houston

    Houston, Texas, 77045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.